HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
3.650
-0.120 (-3.18%)
Jan 6, 2025, 4:00 PM EST - Market closed
HeartSciences Revenue
HeartSciences had revenue of $14.70K in the twelve months ending October 31, 2024, up 151.28% year-over-year. In the fiscal year ending April 30, 2024, HeartSciences had annual revenue of $18.60K with 261.17% growth.
Revenue (ttm)
$14.70K
Revenue Growth
+151.28%
P/S Ratio
180.07
Revenue / Employee
$980
Employees
15
Market Cap
3.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
Apr 30, 2020 | 64.18K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
HSCS News
- 21 days ago - HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement - GlobeNewsWire
- 3 months ago - HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 4 months ago - HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 4 months ago - HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission - GlobeNewsWire
- 5 months ago - HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results - GlobeNewsWire
- 5 months ago - Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency - GlobeNewsWire
- 5 months ago - HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare - GlobeNewsWire